Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse generics. Learn why TAK stock is a buy.

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Australian biotech TekCyte Limited appointed a new co-CEO leadership team consisting of Tony Simula, TekCyte’s founding CEO, as well as Tara James, a commercial strategist and founder of Small and ...

Q4 2024 Earnings Call Transcript May 9, 2025 Christopher O’Reilly: Thank you very much for taking time out of their busy schedule to join our earnings announcement for FY ’24 for Takeda. I’m the ...

The Call for Applications is now open at https://www.innovatorsinscienceaward.com/ and will remain open through September 16, 2025. Shortlisted applicants will be announced in January 2026 and ...

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Takeda Pharmaceutical Co. imply an improvement in the company's underlying business. Investors should show ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 29, 2025 /EINPresswire.com/ -- The tinnitus medical devices market size has grown steadily in recent years. It is expected to grow from $1.84 billion in ...

Learn more about whether Alvotech or Arrowhead Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Those data centers that are equipped to handle AI processing loads are projected to require $5.2 trillion in capital ...